These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21192135)

  • 1. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.
    Skogh E; Sjödin I; Josefsson M; Dahl ML
    J Clin Psychopharmacol; 2011 Feb; 31(1):4-9. PubMed ID: 21192135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid.
    Mao M; Skogh E; Scordo MG; Dahl ML
    J Clin Psychopharmacol; 2012 Apr; 32(2):287-9. PubMed ID: 22388157
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure.
    Söderberg MM; Haslemo T; Molden E; Dahl ML
    Pharmacogenet Genomics; 2013 May; 23(5):279-85. PubMed ID: 23492908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
    Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
    J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.
    Hatta K; Takebayashi H; Sudo Y; Katayama S; Kasuya M; Shirai Y; Morikawa F; Nakase R; Nakamura M; Ito S; Kuga H; Nakamura M; Ohnuma T; Usui C; Nakamura H; Hirata T; Sawa Y;
    Psychiatry Res; 2013 Dec; 210(2):396-401. PubMed ID: 23919898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting.
    Skogh E; Reis M; Dahl ML; Lundmark J; Bengtsson F
    Ther Drug Monit; 2002 Aug; 24(4):518-26. PubMed ID: 12142637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication.
    Theisen FM; Haberhausen M; Schulz E; Fleischhaker C; Clement HW; Heinzel-Gutenbrunner M; Remschmidt H
    Ther Drug Monit; 2006 Dec; 28(6):750-9. PubMed ID: 17164690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.
    Lu ML; Wu YX; Chen CH; Kuo PT; Chen YH; Lin CH; Wu TH
    PLoS One; 2016; 11(2):e0148539. PubMed ID: 26849777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.
    Laika B; Leucht S; Heres S; Schneider H; Steimer W
    Pharmacogenomics J; 2010 Feb; 10(1):20-9. PubMed ID: 19636338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).
    Nozawa M; Ohnuma T; Matsubara Y; Sakai Y; Hatano T; Hanzawa R; Shibata N; Arai H
    Ther Drug Monit; 2008 Feb; 30(1):35-40. PubMed ID: 18223460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
    Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
    J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.
    Czerwensky F; Leucht S; Steimer W
    Ther Drug Monit; 2015 Apr; 37(2):152-60. PubMed ID: 25090458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia.
    An H; Fan H; Chen S; Qi S; Ma B; Shi J; Wang Z; Yang F
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):255-259. PubMed ID: 33814547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients.
    Söderberg MM; Haslemo T; Molden E; Dahl ML
    Pharmacogenomics J; 2013 Dec; 13(6):544-50. PubMed ID: 23147717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients.
    Bergemann N; Frick A; Parzer P; Kopitz J
    Pharmacopsychiatry; 2004 Mar; 37(2):63-8. PubMed ID: 15048613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variables associated with high olanzapine dosing in a state hospital.
    Botts S; Littrell R; de Leon J
    J Clin Psychiatry; 2004 Aug; 65(8):1138-43. PubMed ID: 15323601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taurine and glutathione in plasma and cerebrospinal fluid in olanzapine treated patients with schizophrenia.
    Samuelsson M; Skogh E; Lundberg K; Vrethem M; Öllinger K
    Psychiatry Res; 2013 Dec; 210(3):819-24. PubMed ID: 24113127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters.
    Lu ML; Lin CH; Chen YC; Yang HC; Wu TH
    PLoS One; 2013; 8(5):e65719. PubMed ID: 23741510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.
    Spina E; D'Arrigo C; Santoro V; Muscatello MR; Pandolfo G; Zoccali R; Diaz FJ; de Leon J
    Ther Drug Monit; 2009 Dec; 31(6):758-63. PubMed ID: 19865002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma concentrations of high-dose olanzapine in a double-blind crossover study.
    Kelly DL; Richardson CM; Yu Y; Conley RR
    Hum Psychopharmacol; 2006 Aug; 21(6):393-8. PubMed ID: 16850522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.